







Evonik. Power to create.







Evonik. Power to create.



Our objectives



Innovations

- drive profitable growth at Evonik
- give us access to new products and solutions
- open up attractive areas of business
- strengthen our leading market and technology position

Innovations support our financial targets for 2018

Sales: ~ €18 billion

Adjusted EBITDA: > €3 billion

Our strategy: Focus on megatrends



Innovations provide answers to the global key megatrends:

Health, nutrition

Pharma polymers for targeted drug release

Resource efficiency

SEPURAN® membrane for environmentally friendly purification of biogas

Globalization

Silica-silane technology for tires with lower rolling resistance








Our claim: Customer proximity and market success



- We know our customers and markets
- We take the entire value chain into consideration
- We specifically develop new products that provide a benefit for customers
- We integrate teams from R&D into Sales and Marketing

This enables us to

combine innovation and proximity to customers



Our skills: Research and development



- Selected areas of competence
- Unique technology platforms
- Outstanding process technology and advanced engineering
- Market-oriented research and development
- Creative, efficient research organization

This enables us to


- explore completely new technologies, products, and solutions
- refine our existing products, applications, and processes
- strengthen a balanced innovation pipeline



Our figures in 2012



R&D expenses (millions of €)



- R&D spending of €393 million (+8% compared to previous year)
- Around 2,500 employees at over 35 sites in our global R&D network

R&D at Evonik

- Over 500 R&D projects
- Portfolio of patents and applications filed: over 26,000
- No. of new patent applications filed: approx. 260
- Sales with products younger than 5 years: €1.5 billion







Our fields of innovation



Biotechnology



Electronic materials



Additives for food and feed



Medical devices





New catalytic processes



Membranes



Composites



Cosmetic ingredients

Focus of innovation Biotechnology



Biotechnology in figures 2012

- Sales with products made using biotechnology in the Health & Nutrition Business Unit: over €300 million
- Sales target for 2020: €1 billion with products made using biotechnology in the Health & Nutrition Business Unit
- Investment in Biolys® by 2015: approx. €350 million
- R&D spending on biotechnology: over 10% of R&D spending
- R&D employees: over 200

Biotechnologically manufactured products

- Feed amino acids Biolys[®], ThreAMINO[®], TrypAMINO[®]
- Active pharmaceutical ingredient L-ornithine L-aspartate (LOLA)
- Anti-aging cosmetic actives (hyaluronic acid, ceramides)
- Enzymatically manufactured cosmetic emollients







Our claim: First-class in innovation



Evonik is one of the most innovative companies in the world.

First-class in innovation

Increase the value of the innovation pipeline

New products, applications, and processes must make a substantial contribution to sales and profit

Explore new horizons

Push radical innovation

Cross-BU collaboration

Enhance risk-taking

Trust, openness and transparency

Improve knowledge sharing

